“…The age of participants in included trials ranged from 31 to 57 years. The studies enrolled participants with type 2 diabetes (Azimi et al., 2014 ; Ebrahimi et al., 2019 ; Shahbazian et al., 2019 ), coronary artery disease (Abedimanesh et al., 2020 ), ulcerative sclerosis (Tahvilian et al., 2020 ), multiple sclerosis (Ghiasian et al., 2019 ), nonalcoholic fatty liver (Pour et al., 2020 ), rheumatoid arthritis (Hamidi et al., 2020 ), overweight/obese prediabetic patients (Karimi‐Nazari et al., 2019 ), and methadone maintenance treatment patients (Ghaderi et al., 2019 ). In addition, articles were performed on subjects with various baseline body mass index (BMI) values; nine studies (Abedimanesh et al., 2020 ; Azimi et al., 2014 ; Ebrahimi et al., 2019 ; Ghaderi et al., 2019 ; Giannoulaki et al., 2020 ; Hamidi et al., 2020 ; Karimi‐Nazari et al., 2019 ; Milne et al., 2015 ; Pour et al., 2020 ; Shahbazian et al., 2019 ; Tahvilian et al., 2020 ) were conducted on participants with a BMI over 25 kg/m 2 up to 29.9 kg/m 2 , and one study did not report BMI (Ghiasian et al., 2019 ).…”